Selected publications

Selected publications

Dunn N, Juto A, Ryner M, Manouchehrinia A, Fink K, Piehl A, Fogdell-Hahn A. Rituximab in multiple sclerosis; Frequency and clinical relevance of anti-drug antibodies. Mult Scler. 2018 Aug;24(9):1224-1233.

Engdahl E, Dunn N, Niehusmann P, Wideman S, Wipfler P, Becker AJ, Ekström TJ, Almgren M, Fogdell-Hahn A. Human herpesvirus 6B induces hypomethylation on chromosome 17p13.3 correlating with increased gene expression and virus integration. J Virol. 2017 May 12;91(11).

Link J, Ramanujam R, Auer M, Ryner M, Hässler S, Bachelet D, Mbogning C, Warnke C, Buck D, Hyldgaard Jensen PE, Sievers C, Ingenhoven K, Fissolo N, Lindberg R, Grummel V, Donnellan N, Comabella M, Montalban X, Kieseier B, Soelberg Sørensen P, Hartung HP, Derfuss T, Lawton A, Sikkema D, Pallardy M, Hemmer B, Deisenhammer F, Broët P, Dönnes P, Davidson J, Fogdell-Hahn A; ABIRISK Consortium. Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results. PLoS One. 2017 Feb 7;12(2):e0170395. 

Hermanrud C, Ryner M, Luft T, Jensen PE, Ingenhoven K, Rat D, Deisenhammer F, Sørensen Soelberg P, Pallardy M, Sikkema D, Bertotti E, Kramer D, Creeke P, Fogdell-Hahn A, on behalf of the ABIRISK consortium. Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta. J Immunol Methods. 2016 Mar;430:1-9.  

Link J, Lundkvist Ryner M, Fink K, Hermanrud C, Lima Bomfim I, Brynedal B, Kockum I, Hillert J, Fogdell-Hahn A. Human leukocyte antigen genes and interferon beta preparation influence on risk of developing neutralizing anti-drug antibodies in multiple sclerosis. PLoS One. 2014 Mar 7;9(3):e90479.

Warnke C, Ramanujam R, Plavina T, Bergström T, Goelz S, Subramanyam M, Kockum I, Rahbar A, Kieseier BC, Holmén C, Olsson T, Hillert J, Fogdell-Hahn A. Changes to anti-JCV antibody levels in a Swedish national MS cohort. J Neurol Neurosurg Psychiatry 2013;0:1–7. 

Lundkvist M, Engdahl E, Holmén C, Movérare R, Olsson T, Hillert J, Fogdell-Hahn A. Characterization of anti-natalizumab antibodies in multiple sclerosis patientsMult Scler. 2013 May;19(6):757-64. 

Jungedal R, Lundkvist M, Engdahl E, Ramanujam R, Westerlind H, Sominanda A, Hillert J, Fogdell-Hahn A. Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice. Mult Scler. 2012 Dec;18(12):1775-81. 

Sominanda A, Hillert J, Fogdell-Hahn A. In vivo bioactivity of interferon beta in multiple sclerosis patients with neutralizing antibodies is titer dependentJ Neurol Neurosurg Psychiatry. 2008 Jan;79(1):57-62. 

Hammarstedt M, Ahlqvist J, Jacobson S, Garoff H, Fogdell-Hahn. Purification of infectious Human herpesvirus 6A virions and association of host cell proteinsVirology Journal. 2007 Oct 19;4:101. 

Fotheringham J, Donati D, Akhyani N, Fogdell Hahn A, Vortmeyer A, John D. Heiss JD, Williams E, Weinstein S, Bruce DA, Gaillard WD, Sato S, Theodore WH, Jacobson S. Association of human herpesvirus 6B with mesial temporal lobe epilepsy. PLoS Med. 2007 May;4(5):e180.

Ahlqvist J, Donati D, Martinelli E, Akhyani N, Hou J, Major EO, Fogdell-Hahn A*, Jacobson S* (*shared senior authorship). Complete replication cycle and acquisition of tegument in nucleus of Human herpesvirus 6A (HHV-6A) in astrocytes and in T-cells. J Med Virol. 2006 Dec;78(12):1542-53.